| Style | Citing Format |
|---|---|
| MLA | Hatami P, et al.. "Remaining Molecular Scarring in the Skin of Patients With Psoriasis: What Are the Reversal Factors?." Clinical Immunology, vol. 283, no. , 2026, pp. -. |
| APA | Hatami P, Nicknam Asl H, Aryanian Z, Khayyat A, Homayouni M, Mostaghimi A (2026). Remaining Molecular Scarring in the Skin of Patients With Psoriasis: What Are the Reversal Factors?. Clinical Immunology, 283(), -. |
| Chicago | Hatami P, Nicknam Asl H, Aryanian Z, Khayyat A, Homayouni M, Mostaghimi A. "Remaining Molecular Scarring in the Skin of Patients With Psoriasis: What Are the Reversal Factors?." Clinical Immunology 283, no. (2026): -. |
| Harvard | Hatami P et al. (2026) 'Remaining Molecular Scarring in the Skin of Patients With Psoriasis: What Are the Reversal Factors?', Clinical Immunology, 283(), pp. -. |
| Vancouver | Hatami P, Nicknam Asl H, Aryanian Z, Khayyat A, Homayouni M, Mostaghimi A. Remaining Molecular Scarring in the Skin of Patients With Psoriasis: What Are the Reversal Factors?. Clinical Immunology. 2026;283():-. |
| BibTex | @article{ author = {Hatami P and Nicknam Asl H and Aryanian Z and Khayyat A and Homayouni M and Mostaghimi A}, title = {Remaining Molecular Scarring in the Skin of Patients With Psoriasis: What Are the Reversal Factors?}, journal = {Clinical Immunology}, volume = {283}, number = {}, pages = {-}, year = {2026} } |
| RIS | TY - JOUR AU - Hatami P AU - Nicknam Asl H AU - Aryanian Z AU - Khayyat A AU - Homayouni M AU - Mostaghimi A TI - Remaining Molecular Scarring in the Skin of Patients With Psoriasis: What Are the Reversal Factors? JO - Clinical Immunology VL - 283 IS - SP - EP - PY - 2026 ER - |